While announcing billions of dollars in new U.S. investments, company chief David Ricks called for an extension of 2017 tax ...

The British drugmaker claimed study success in a first-line setting in breast cancer. Elsewhere, Rezdiffra sales continued to ...

CiteAb, a Sci-Tech company specialising in data collection, announces the launch of CiteAb Unlimited for pharmaceutical and biotechnology companies. This service provides private access to a database ...

The company is doubling plans for capital spending on U.S. factories as President Donald Trump pressures the pharma industry ...

If you have concerns about your use of Depo-Provera, we would like to hear from you. Please complete the contact form on this page, send us an email at info@classlawdc.com, or give us a call at (202) ...

The funding comes as Eikon, run by former Merck research chief Roger Perlmutter, has started a Phase 3 trial testing one of ...

Telehealth provider Hims & Hers said it will tell consumers they need to seek “alternative options on the commercial dosing,” ...

Ten of 11 children born with a rare form of congenital hearing loss experienced improvements after receiving the company’s ...

An industry source said “most, if not all” of the people at CDRH who were recently dismissed are now being asked to return.

DiveWire guarantees visibility for your news announcements through instant distribution to BioPharma Dive’s audience and its 176,000 newsletter subscribers for 21 days.

The partners will test Summit’s ivonescimab alongside Pfizer’s antibody-drug conjugates in hopes of finding “potentially ...

Mirum gained the drug, which it will sell as Ctexli for adults with cerebrotendinous xanthomatosis, in a 2023 deal with ...